Revolution Medicines guides 2024 net loss $560-600M; RMC-6236 shows 8.1-month PFS in 2L PDAC, Phase 3 planned

Revolution Medicines, Inc.

Net loss for FY2024 expected $560-600M, including $70-80M non-cash stock-based comp.
Cash runway into 2027; current cash, equivalents, and marketable securities sufficient.
RMC-6236 in 2L metastatic PDAC: median PFS 8.1 months (KRAS G12X); ORR 27% (20+ weeks treatment).
Safety: 96% any-grade TRAEs, 22% Grade ≥3; 0% discontinuation; dose intensity 94%.
Plans to initiate randomized Phase 3 RASolute 302 in 2H 2024 vs investigator's choice chemo.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.